Navigation Links
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Date:1/18/2008

- INTELENCE is the first NNRTI to show antiviral activity in patients with

NNRTI-resistant virus -

BRIDGEWATER, N.J., Jan. 18 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted accelerated approval to the anti-HIV medication INTELENCE (etravirine) tablets -- the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to show antiviral activity in treatment- experienced adult patients with HIV resistant to a NNRTI and other antiretroviral (ARV) agents. INTELENCE, also known as TMC125, was developed by Tibotec Pharmaceuticals, Ltd. and will be marketed in the U.S. by Tibotec Therapeutics, a division of Ortho Biotech Products, L.P.

"NNRTIs have been used in HIV combination therapy for more than a decade, but their use has been limited by cross-resistance within the class. Resistance to one NNRTI generally meant resistance to all NNRTIs," said Richard Haubrich, M.D., Professor of Medicine, Division of Infectious Diseases, University of California, San Diego, and investigator in the INTELENCE Phase 3 DUET studies. "Etravirine breaks new ground in the NNRTI class, and provides a new option to thousands of treatment-experienced patients with NNRTI-resistant HIV."

INTELENCE, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to a NNRTI and other ARV agents.

This indication is based on Week 24 analyses from two randomized, double-blind, placebo-controlled trials of INTELENCE. Both studies were conducted in clinically advanced, three-class antiretroviral (NNRTI, N[t]RTI, PI) treatment-experienced adults.

The following points should be considered when initiating therapy with INTELENCE:

-- Treatment history and, when available, resistance testing, should guide


'/>"/>

SOURCE Tibotec Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
2. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
3. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
4. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
5. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
6. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
7. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
10. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
11. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... Nov. 9 BioMed Realty Tr...ompany has received commitments from lenders to in...e of credit by $65 million to an aggregate of $665...e facility. The weighted-average effective intere...as of September 30, 2009. The maturity date remain...
(Date:11/9/2009)... Nov. 9 NexBio, Inc. announced the...can College of Allergy, Asthma, and Immunology in ...S181 (Fludase®), a Sialidase, Decreases Airwa...cts in Animal Models of Asthma". ,, DAS181 (Flu... host-targeting drug candidate being studied in hu...
(Date:11/9/2009)... Product release is a research industry f...rch facilities and research safety study data to b... Cedar Knolls, NJ (PRWEB) November ...that it has unveiled Pristima™ VM, an integr...ilities that track the use and care of veterinary ...
(Date:11/8/2009)...N VIEW, Calif. Nov. 5, 2009 Complete Genomics, a... today announced publication of a report in the jo...uencing platform, including analysis of sequence d...bles cost for these three genomes sequenced on the...from $8,005 for 87x coverage to $1,726 for 45x cov...
Breaking Biology Technology:BioMed Realty Trust Receives Commitments to Expand Unsecured Line of Credit to $665 Million 2BioMed Realty Trust Receives Commitments to Expand Unsecured Line of Credit to $665 Million 3NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 2NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 3Xybion Unveils Pristima™ VM, an Integrated Enterprise Software Solution for Vivarium and Veterinary Care Management 2Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes 2
...., March 4 Vermillion, Inc.,(Nasdaq: VRMLD ), a ...ecent,accomplishments across its diagnostic test p...estones it plans to achieve over the course of 200... the fourth quarter and year,ended December 31, 20...al and commercial,advancements in our diagnostic p...
... 4 On Wednesday, March 5, 2008,at 8:30 a.m. Easte...me,members of Cell Therapeutics, Inc.,s (CTI) (Nas...ost a conference call to discuss the company,s rec... structure, and upcoming,product and sales milesto...bers Wednesday, March 5...
...E, Fla., March 4 Imaging,Diagnostic Systems, Inc....tical breast imaging systems, will exhibit CT Lase...uropean Congress of Radiology (ECR 2008), March,7-...xpo E #566., (Logo: http://www.newscom.com/cgi-b...be a part of ECR 2008," commented Deborah O,Brien,...
Other Biology Technology:Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 2Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 3Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 4Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 5Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 6Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 7Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 8Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 9Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones 2CT Laser Mammography Technology to be Featured at European Congress of Radiology 2
(Date:11/9/2009)...turwissenschaften is publishing a special issue "...gy" to commemorate Darwin,s On the Origin of Speci...859. Guest editor and author of the lead article i...ogy and evolutionary biology at the University of ...sue are available free of charge until 30 December...
(Date:11/9/2009)...ponsible for the rapid, mysterious death of phytop... by collaborating scientists at Rutgers University...I). This same chemical may hold unexpected promis...eviously unknown lipid, or fatty compound, in a vi... huxleyi , a phytoplankton that plays a major role...
(Date:11/8/2009)...IGNED FOR ADULTS WITH INTELLECTUAL DISABILITIES: A...University study involving adults with intellectua...ir personal health knowledge after taking a semi-w...n internationally accepted term for mental retarda...cal inactivity and preventable chronic diseases co...
Breaking Biology News(10 mins):Newly discovered fat molecule: An undersea killer with an upside 2Newly discovered fat molecule: An undersea killer with an upside 3Newly discovered fat molecule: An undersea killer with an upside 4Indiana U. at APHA: Studies about health education for people with ID, stability balls at work 2Indiana U. at APHA: Studies about health education for people with ID, stability balls at work 3Prestigious 244 9 million NIH grant awarded to Case Western Reserve for colon cancer research 10077 1Prestigious 244 9 million NIH grant awarded to Case Western Reserve for colon cancer research 10077 2RetireSafe to Senate 3A Stop Proposed Rationing of High Quality Hospital Care Medicare Needs More Physician Hospitals 58219 1RetireSafe to Senate 3A Stop Proposed Rationing of High Quality Hospital Care Medicare Needs More Physician Hospitals 58219 2Physician Reimbursement and Their Practice Survival Defended by American National Medical Management 58214 1Physician Reimbursement and Their Practice Survival Defended by American National Medical Management 58214 2
...er 100 scientists worldwide publish joint study in...a, Asia, Europe and the US have been probing the g...l years. Their results in some aspects have comple...ns. The findings are available in the prestigious ...lusion of the study is that the genome of mammals ...
...w insects avoid getting diseases they can carry an...sas State University. , Mike Kanost, university di...the department of biochemistry, and researchers in...es against infection. They think the answer lies i...searchers have made progress in understanding whic...
...study published in the latest issue of Restoration...eefs help to deter erosion. Oyster reefs are self...se they use native materials, have the potential f...system stability and quality. , Oyster larvae move... oysters, settlement; reefs are therefore able to ...
Other Biology News:Mouse genome much more complex than expected 2K-State researchers study insects' immune system 2
... Rotofor purification system with PowerPac 3000 po...ion and purification by liquid-phase isoelectric f...18 ml) and standard (60 ml) focusing chambers, cha...ode chambers, PowerPac 3000 power supply, 10 ml Bi...
Anti-Connexin 45 (Cx45), Near C-terminus, cytoplasmic Monoclonal Antibody, Unconjugated, Clone 5B9.2 from CHEMICON
NBT/BCIP Chromogen System (SIGNET) from Covance Research Products, Inc
... Infinite 200 series of microplate readers combine...ce or absorbance detection in an affordable, easy-...ence applications. The unique modular design and a...searchers with a choice of a monochromator (M200) ...
Biology Products: